AstraZeneca

What science can do

AstraZeneca Annual Report and Form 20-F Information 2022

AstraZeneca at a Glance

We are transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.

Our strategic priorities

Our priorities reflect how we are working to deliver our growth through innovation strategy and achieve our Purpose of pushing the boundaries of science to deliver life-changing medicines.

1. Science and Innovation
2. Growth and Therapy Area Leadership
3. People and Sustainability

Science and innovation-led

We use our distinctive scientific capabilities to deliver a pipeline of life-changing medicines.

Distinctive R&D capabilities

179 projects in our development pipeline[1]

15 NMEs in our late-stage pipeline

121 NME or major LCM projects in Phase II and Phase III



Phase I | Phase II | Late-stage development | Life-cycle management projects

[1] Includes NME and major LCM projects up to launch in all applicable major markets.

Leading in our Therapy Areas

Focused on areas where we can make the most meaningful difference to patients.

Therapy Areas

Oncology
BioPharmaceuticals
Rare Disease

Total Revenue[2]

$44.4bn



[2] Total Revenue includes revenues from Other Medicines. See page 33.

Broad-based, diverse source of business

Diversified portfolio across primary, specialty care and rare disease with a global reach.

Total Revenue by Therapy Area



- Oncology 35%
- BioPharmaceuticals 45%
- Rare Disease 16%
- Other Medicines 4%

Total Revenue by reporting region[3]



- US 40%
- Emerging Markets 26%
- Europe 20%
- Established Rest of World 13%

[3] Due to rounding, the sum of percentages above does not equal 100%.



Oncology. See from page 18.



BioPharmaceuticals. See from page 22.



Rare Disease. See from page 30.

Commitment to our people

We are empowering our people to reach their full potential in a dynamic, inclusive and high-performing working environment.

For more information, see from page 44.

83,500
employees
2021: 83,100
2020: 76,100

49.5%
of our senior roles are filled by women

Employees by reporting region



Commitment to society

We are harnessing the power of Science and Innovation to deliver a positive impact to society, healthcare systems and the environment.

For more information, see from page 48.

Priority 1

Access to healthcare

Increasing access to life-saving treatments, promoting prevention, and strengthening global health system resilience and sustainability.

Priority 2

Environmental protection

Accelerating the delivery of net-zero healthcare, managing our environmental impact, and investing in nature and biodiversity.

Priority 3

Ethics and transparency

Ensuring ethical, open, and inclusive behaviour across our organisation and value chain.

access to medicine index

3rd overall and #1 for Product Delivery

CDP
DRIVING SUSTAINABLE ECONOMIES

Double A List for Climate Change and Water Security

MEMBER OF Dow Jones Sustainability Indices
In Collaboration with RobecoSAM

World and Europe constituent

Bloomberg Gender-Equality Index

Bloomberg Gender-Equality Index listing

Global reach and presence

Our R&D organisation has more than 13,000 employees across our global sites. We have four strategic R&D centres: Cambridge, UK; Boston, MA, US; Gaithersburg, MD, US; and Gothenburg, Sweden, as well as seven other R&D centres and offices.



Global R&D centres

1. Cambridge, UK (HQ)
2. Boston, MA, US
3. Gaithersburg, MD, US
4. Gothenburg, Sweden

28 manufacturing sites in 16 countries

Other R&D centres and offices

5. San Francisco, CA, US
6. New York, NY, US
7. New Haven, CT, US
8. Alderley Park, UK
9. Macclesfield, UK
10. Shanghai, China
11. Osaka, Japan